Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-Label, Parallel-Group Study to Assess the Safety and Pharmacokinetics of Oral Epetraborole Tablets in Adult Subjects With Varying Degrees of Renal Function

NCT05283746 is registered in ClinicalTrials.gov with AN2 Therapeutics, Inc as lead sponsor.

NCT NCT05283746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05283746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-Label, Parallel-Group Study to Assess the Safety and Pharmacokinetics of Oral Epetraborole Tablets in Adult Subjects With Varying Degrees of Renal Function
Lead sponsor
AN2 Therapeutics, Inc
Phase
Phase 1
Overall status
Completed
Start date
February 21, 2022
Completion date
June 27, 2022
Enrollment
40 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

renal insufficiency